Related Experiment Video

Updated: Jul 6, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Can FLT3 inhibitors overcome resistance in AML?

Winnie F Tam1, D Gary Gilliland

  • 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Best Practice & Research. Clinical Haematology
|March 18, 2008
PubMed

Insights

FLT3 mutations in acute myeloid leukemia (AML) offer targeted therapy options. Further research into resistance mechanisms and optimizing FLT3 inhibitor combinations with chemotherapy is crucial for improved AML treatment.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent in acute myeloid leukemia (AML).
  • Targeted therapies for FLT3-mutated AML are under clinical investigation.
  • Current FLT3 inhibitors show promise but require further optimization.

Purpose of the Study:

  • To review the potential of FLT3 inhibitors in AML treatment.
  • To highlight the need for understanding resistance mechanisms.
  • To explore optimizing FLT3 inhibitor integration with chemotherapy.

Main Methods:

  • Review of current clinical trials involving FLT3 inhibitors in AML.
  • Analysis of existing data on FLT3 inhibitor efficacy and toxicity.
  • Discussion of genetic resistance mechanisms to FLT3 inhibitors.

Main Results:

  • Four FLT3 inhibitors are in clinical trials for AML.
  • At least three agents demonstrate significant activity and acceptable toxicity.
  • Understanding resistance is key for developing next-generation agents.

Conclusions:

  • FLT3 inhibitors represent a promising targeted therapy for AML.
  • Further research is needed to overcome resistance and optimize treatment strategies.
  • Combining FLT3 inhibitors with chemotherapy may improve outcomes and reduce toxicity.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...